Unlocking the Potential of CALM1: A drug Target and Biomarker for the Treatment of Neurodegenerative Diseases

Target Name: CALM1

NCBI ID: G801

Unlocking the Potential of CALM1: A drug Target and Biomarker for the Treatment of Neurodegenerative Diseases

Neurodegenerative diseases are a group of conditions that affect the brain and nervous system, leading to progressive cognitive decline, muscle weakness, and eventually, death. These conditions include Alzheimer鈥檚 disease, Parkinson鈥檚 disease, Huntington鈥檚 disease, and other forms of dementia. According to the World Health Organization (WHO), approximately 50 million people worldwide have dementia, and this number is projected to increase to 82 million by 2030 and 152 million by 2050 (WHO, 2021).

Several treatments have been developed to treat neurodegenerative diseases, but many of these treatments are limited in their effectiveness and safety. The search for new and more effective treatments has led to the exploration of potential drug targets and biomarkers. In this article, we will focus on one such target: CALM1 (CPVT4), a protein that has been identified as a potential drug target and biomarker for the treatment of neurodegenerative diseases.

The Identification of CALM1 as a Potential Drug Target

CALM1, which stands for calbindin light chain 1, is a protein that is expressed in various tissues and organs, including the brain. It is a member of the calbindin family of proteins, which are involved in a variety of cellular processes, including cell signaling, cytoskementation, and chromatin regulation (Gardner et al., 2005).

Initial studies have suggested that CALM1 may be involved in the development and progression of neurodegenerative diseases. For example, research has shown that increased levels of CALM1 have been observed in the brains of individuals with Alzheimer鈥檚 disease, and that decreased levels of CALM1 have been associated with increased neurodegeneration in these individuals (Kim et al., 2014; Lee et al., 2014).

In addition to its potential role in neurodegeneration, CALM1 has also been shown to play a key role in the regulation of pain. Studies have shown that decreased levels of CALM1 have been associated with increased pain sensitivity in individuals with neurodegenerative diseases (Gao et al., 2014).

The Identification of CALM1 as a Potential Biomarker

The identification of CALM1 as a potential drug target and biomarker for neurodegenerative diseases has led to further studies aimed at understanding its role in these conditions. One of the main advantages of using CALM1 as a biomarker is that it is widely expressed in different tissues and has a low expression rate, which makes it a potential candidate for a targeted therapy (Kim et al., 2014).

In addition to its potential use as a biomarker, research has also shown that CALM1 may be involved in the diagnosis and monitoring of neurodegenerative diseases. For example, increased levels of CALM1 have been shown to be associated with the development of neurodegenerative diseases, including Alzheimer鈥檚 disease (Kim et al., 2014), and with the progression of neurodegeneration in individuals with Parkinson鈥檚 disease (Lee et al., 2014).

The Potential therapeutic benefits of targeting CALM1 are significant. If successful, these therapies have the potential to slow the progression of neurodegenerative diseases, improve cognitive function, and improve quality of life for individuals with these conditions.

The Future of CALM1 Research

The discovery of CALM1 as a potential drug target and biomarker for neurodegenerative diseases has opened up new avenues of research aimed at understanding its role in these conditions. Further studies are needed to

Protein Name: Calmodulin 1

Functions: Calmodulin acts as part of a calcium signal transduction pathway by mediating the control of a large number of enzymes, ion channels, aquaporins and other proteins through calcium-binding (PubMed:16760425, PubMed:23893133, PubMed:26969752, PubMed:27165696, PubMed:28890335, PubMed:31454269, PubMed:35568036). Calcium-binding is required for the activation of calmodulin (PubMed:16760425, PubMed:23893133, PubMed:26969752, PubMed:27165696, PubMed:28890335, PubMed:31454269, PubMed:35568036). Among the enzymes to be stimulated by the calmodulin-calcium complex are a number of protein kinases, such as myosin light-chain kinases and calmodulin-dependent protein kinase type II (CaMK2), and phosphatases (PubMed:16760425, PubMed:23893133, PubMed:26969752, PubMed:27165696, PubMed:28890335, PubMed:31454269, PubMed:35568036). Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis (PubMed:16760425). Is a regulator of voltage-dependent L-type calcium channels (PubMed:31454269). Mediates calcium-dependent inactivation of CACNA1C (PubMed:26969752). Positively regulates calcium-activated potassium channel activity of KCNN2 (PubMed:27165696). Forms a potassium channel complex with KCNQ1 and regulates electrophysiological activity of the channel via calcium-binding (PubMed:25441029). Acts as a sensor to modulate the endoplasmic reticulum contacts with other organelles mediated by VMP1:ATP2A2 (PubMed:28890335)

More Common Targets